LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma

Chen Lossos, Soley Bayraktar, Elizabeth Weinzierl, Sheren F. Younes, Peter Hosein, Robert J. Tibshirani, Jocelyn Sutton Posthumus, Lisa M. Deangelis, Jeffrey Raizer, David Schiff, Lauren Abrey, Yasodha Natkunam, Izidore Lossos

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Primary central nervous system lymphoma (PCNSL) is an aggressive sub-variant of non-Hodgkin lymphoma (NHL) with morphological similarities to diffuse large B-cell lymphoma (DLBCL). While methotrexate (MTX)-based therapies have improved patient survival, the disease remains incurable in most cases and its pathogenesis is poorly understood. We evaluated 69 cases of PCNSL for the expression of HGAL (also known as GCSAM), LMO2 and BCL6 - genes associated with DLBCL prognosis and pathobiology, and analysed their correlation to survival in 49 PCNSL patients receiving MTX-based therapy. We demonstrate that PCNSL expresses LMO2, HGAL(also known as GCSAM) and BCL6 proteins in 52%, 65% and 56% of tumours, respectively. BCL6 protein expression was associated with longer progression-free survival (P = 0·006) and overall survival (OS, P = 0·05), while expression of LMO2 protein was associated with longer OS (P = 0·027). Further research is needed to elucidate the function of BCL6 and LMO2 in PCNSL.

Original languageEnglish
Pages (from-to)640-648
Number of pages9
JournalBritish Journal of Haematology
Volume165
Issue number5
DOIs
StatePublished - Jan 1 2014

Fingerprint

Lymphoma
Central Nervous System
Survival
Lymphoma, Large B-Cell, Diffuse
Methotrexate
Proteins
Non-Hodgkin's Lymphoma
Disease-Free Survival
Therapeutics
Research
Genes
Neoplasms

Keywords

  • BCL6
  • HGAL
  • LMO2
  • PCNSL
  • Prognosis

ASJC Scopus subject areas

  • Hematology

Cite this

LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma. / Lossos, Chen; Bayraktar, Soley; Weinzierl, Elizabeth; Younes, Sheren F.; Hosein, Peter; Tibshirani, Robert J.; Sutton Posthumus, Jocelyn; Deangelis, Lisa M.; Raizer, Jeffrey; Schiff, David; Abrey, Lauren; Natkunam, Yasodha; Lossos, Izidore.

In: British Journal of Haematology, Vol. 165, No. 5, 01.01.2014, p. 640-648.

Research output: Contribution to journalArticle

Lossos, C, Bayraktar, S, Weinzierl, E, Younes, SF, Hosein, P, Tibshirani, RJ, Sutton Posthumus, J, Deangelis, LM, Raizer, J, Schiff, D, Abrey, L, Natkunam, Y & Lossos, I 2014, 'LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma', British Journal of Haematology, vol. 165, no. 5, pp. 640-648. https://doi.org/10.1111/bjh.12801
Lossos, Chen ; Bayraktar, Soley ; Weinzierl, Elizabeth ; Younes, Sheren F. ; Hosein, Peter ; Tibshirani, Robert J. ; Sutton Posthumus, Jocelyn ; Deangelis, Lisa M. ; Raizer, Jeffrey ; Schiff, David ; Abrey, Lauren ; Natkunam, Yasodha ; Lossos, Izidore. / LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma. In: British Journal of Haematology. 2014 ; Vol. 165, No. 5. pp. 640-648.
@article{f6ae146a91684af186462c83d2fda807,
title = "LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma",
abstract = "Primary central nervous system lymphoma (PCNSL) is an aggressive sub-variant of non-Hodgkin lymphoma (NHL) with morphological similarities to diffuse large B-cell lymphoma (DLBCL). While methotrexate (MTX)-based therapies have improved patient survival, the disease remains incurable in most cases and its pathogenesis is poorly understood. We evaluated 69 cases of PCNSL for the expression of HGAL (also known as GCSAM), LMO2 and BCL6 - genes associated with DLBCL prognosis and pathobiology, and analysed their correlation to survival in 49 PCNSL patients receiving MTX-based therapy. We demonstrate that PCNSL expresses LMO2, HGAL(also known as GCSAM) and BCL6 proteins in 52{\%}, 65{\%} and 56{\%} of tumours, respectively. BCL6 protein expression was associated with longer progression-free survival (P = 0·006) and overall survival (OS, P = 0·05), while expression of LMO2 protein was associated with longer OS (P = 0·027). Further research is needed to elucidate the function of BCL6 and LMO2 in PCNSL.",
keywords = "BCL6, HGAL, LMO2, PCNSL, Prognosis",
author = "Chen Lossos and Soley Bayraktar and Elizabeth Weinzierl and Younes, {Sheren F.} and Peter Hosein and Tibshirani, {Robert J.} and {Sutton Posthumus}, Jocelyn and Deangelis, {Lisa M.} and Jeffrey Raizer and David Schiff and Lauren Abrey and Yasodha Natkunam and Izidore Lossos",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/bjh.12801",
language = "English",
volume = "165",
pages = "640--648",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma

AU - Lossos, Chen

AU - Bayraktar, Soley

AU - Weinzierl, Elizabeth

AU - Younes, Sheren F.

AU - Hosein, Peter

AU - Tibshirani, Robert J.

AU - Sutton Posthumus, Jocelyn

AU - Deangelis, Lisa M.

AU - Raizer, Jeffrey

AU - Schiff, David

AU - Abrey, Lauren

AU - Natkunam, Yasodha

AU - Lossos, Izidore

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Primary central nervous system lymphoma (PCNSL) is an aggressive sub-variant of non-Hodgkin lymphoma (NHL) with morphological similarities to diffuse large B-cell lymphoma (DLBCL). While methotrexate (MTX)-based therapies have improved patient survival, the disease remains incurable in most cases and its pathogenesis is poorly understood. We evaluated 69 cases of PCNSL for the expression of HGAL (also known as GCSAM), LMO2 and BCL6 - genes associated with DLBCL prognosis and pathobiology, and analysed their correlation to survival in 49 PCNSL patients receiving MTX-based therapy. We demonstrate that PCNSL expresses LMO2, HGAL(also known as GCSAM) and BCL6 proteins in 52%, 65% and 56% of tumours, respectively. BCL6 protein expression was associated with longer progression-free survival (P = 0·006) and overall survival (OS, P = 0·05), while expression of LMO2 protein was associated with longer OS (P = 0·027). Further research is needed to elucidate the function of BCL6 and LMO2 in PCNSL.

AB - Primary central nervous system lymphoma (PCNSL) is an aggressive sub-variant of non-Hodgkin lymphoma (NHL) with morphological similarities to diffuse large B-cell lymphoma (DLBCL). While methotrexate (MTX)-based therapies have improved patient survival, the disease remains incurable in most cases and its pathogenesis is poorly understood. We evaluated 69 cases of PCNSL for the expression of HGAL (also known as GCSAM), LMO2 and BCL6 - genes associated with DLBCL prognosis and pathobiology, and analysed their correlation to survival in 49 PCNSL patients receiving MTX-based therapy. We demonstrate that PCNSL expresses LMO2, HGAL(also known as GCSAM) and BCL6 proteins in 52%, 65% and 56% of tumours, respectively. BCL6 protein expression was associated with longer progression-free survival (P = 0·006) and overall survival (OS, P = 0·05), while expression of LMO2 protein was associated with longer OS (P = 0·027). Further research is needed to elucidate the function of BCL6 and LMO2 in PCNSL.

KW - BCL6

KW - HGAL

KW - LMO2

KW - PCNSL

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84900483533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900483533&partnerID=8YFLogxK

U2 - 10.1111/bjh.12801

DO - 10.1111/bjh.12801

M3 - Article

VL - 165

SP - 640

EP - 648

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -